Search
Lymphoma Paid Clinical Trials in Massachusetts
A listing of 114 Lymphoma clinical trials in Massachusetts actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
61 - 72 of 114
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Lymphoma
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
The state of Massachusetts currently has 114 active clinical trials seeking participants for Lymphoma research studies. These trials are conducted in various cities, including Boston, Worcester, Springfield and Burlington.
Featured Trial
Major Depressive Disorder Clinical Study
Recruiting
Is depression weighing you down? Local major depressive disorder clinical studies are now enrolling participants in the area. Participating in research studies helps contribute to the advancement of future medicine and treatment options. There is no obligation to take part and health insurance is not required.
Conditions:
Major Depressive Disorder
Major Depression
Major Depressive Episode
Major Depressive Disorder (MDD)
Major Depressive Disorders
Featured Trial
Hyperacusis Activities Treatment-Online Study
Recruiting
Are you experiencing hyperacusis? If so, we are recruiting adults with hyperacusis to complete a clinical trial supported by the National Institutes of Health. The study involves participating in a remote counseling program and sound therapy trial for hyperacusis, Hyperacusis Activities Treatment-Online.
Conditions:
Hyperacusis
Tinnitus
Hearing Loss
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Irritability Associated with Autism (Children and Adolescents) Study
Recruiting
Become part of a clinical trial today and play a role in driving medical research forward, aiding in the discovery of groundbreaking therapies. Get rewarded for your time with monetary compensation and enjoy access to medical treatment at no charge.
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Recruiting
A multicenter, open-label Phase 2b study of selinexor (KPT-330) in participants with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who have no therapeutic options of demonstrated clinical benefit.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/27/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts +3 locations
Conditions: Diffuse Large B-cell Lymphoma
AZD3470 as Monotherapy and in Combination With Anticancer Agents in Participants With Relapsed/Refractory Haematologic Malignancies.
Recruiting
This study is designed to evaluate the safety, tolerability, PK and preliminary efficacy following oral administration of AZD3470 as a monotherapy, and in combination with other anticancer agents in participants with haematologic malignancies.
Gender:
All
Ages:
Between 15 years and 130 years
Trial Updated:
03/25/2024
Locations: Research Site, Boston, Massachusetts
Conditions: Lymphoma, Non-Hodgkin, Hodgkin Lymphoma
Interactive Survivorship Program for the Improvement of Healthcare Resources in Adolescent and Young Adult Cancer Survivors, INSPIRE-AYA Study
Recruiting
This trial studies how well an interactive survivorship program works in improving healthcare resources in adolescent and young adult cancer survivors. By improving access to survivorship resources, health literacy, self-management skills, and support, an interactive survivorship program may help to improve adherence to adolescent and young adult healthcare guidelines and reduce cancer-related distress.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/20/2024
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage II Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Melanoma AJCC v8, Hematopoietic and Lymphoid Cell Neoplasm, Invasive Malignant Neoplasm, Leukemia, Lymphoma, Malignant Solid Neoplasm, Sarcoma, Stage I Colorectal Cancer AJCC v8, Stage II Colorectal Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Thyroid Gland Carcinoma
WTX-330 in Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma
Recruiting
A first-in-human, Phase 1, open-label, multicenter study of WTX-330 administered as a monotherapy to patients with advanced or metastatic solid tumors or non-Hodgkin lymphoma.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/19/2024
Locations: Mass General Hospital, Boston, Massachusetts
Conditions: Advanced or Metastatic Solid Tumors, Non-Hodgkin Lymphoma
Immune and Genomic Markers in ALK+ NSCLC
Recruiting
The purpose of this research study is to obtain and study clinical history, and tissue and saliva specimens if available from participants with Anaplastic Lymphoma Kinase-ALK+ Non-Small Lung Cancer(NSCLC)
Gender:
All
Ages:
18 years and above
Trial Updated:
03/15/2024
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Conditions: Anaplastic Lymphoma Kinase Gene Translocation, Non-Small Cell Lung Cancer
A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma
Recruiting
The purpose of this study is to define the recommended Phase 2 Dose, safety, tolerability, immunogenicity, and preliminary efficacy of EO2463 during monotherapy and in combination with lenalidomide and/or rituximab in patients with indolent NHL
Gender:
All
Ages:
18 years and above
Trial Updated:
03/14/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Follicular Lymphoma, Marginal Zone Lymphoma
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Recruiting
This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications.
Gender:
All
Ages:
All
Trial Updated:
03/14/2024
Locations: Tufts Medical Center, Boston, Massachusetts +4 locations
Conditions: Hematologic Malignancies, Inherited Disorders of Metabolism, Inherited Abnormalities of Platelets, Histiocytic Disorders, Acute Myelogenous Leukemia (AML or ANLL), Acute Lymphoblastic Leukemia (ALL), Other Acute Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases, Other Leukemia, Hodgkin Lymphoma, Non-hodgkin Lymphoma, Multiple Myeloma/ Plasma Cell Disorder (PCD), Inherited Abnormalities of Erythrocyte Differentiation or Function, Disorders of the Immune System, Severe Aplastic Anemia, Autoimmune Diseases
Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Recruiting
The study is intended to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of AZD7789 in patients with relapsed/refractory classical Hodgkin Lymphoma (r/r cHL).
Gender:
All
Ages:
Between 16 years and 101 years
Trial Updated:
03/13/2024
Locations: Research Site, Boston, Massachusetts
Conditions: Relapsed or Refractory Classical Hodgkin Lymphoma
UPLYFT For Lymphoma Survivors
Recruiting
The main purpose of this study is to field test and pilot an intervention called UPLYFT (Understand and Prevail: Lymphoma Fear of Recurrence Therapy) that includes information about lymphoma survivorship and tools to improve quality of life and reduce lymphoma-related worries among lymphoma survivors.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/06/2024
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Lymphoma, Survivorship
Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies
Recruiting
The purpose of this study is to investigate possible genetic factors that contribute to the development of lymphomas. The databank will be used to determine whether familial lymphomas have unique genetic characteristics different from sporadic lymphomas and to attempt to identify a gene that confers an increased risk of lymphoma.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/04/2024
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Non-Hodgkin's Lymphoma, Hodgkin's Disease, Leukemia, Lymphocytic, Chronic, Lymphoproliferative Disorders
Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma
Recruiting
First-in-human, open-label, dose-finding and dose-expansion study of UCART20x22 administered intravenously in subjects with relapsed or refractory B-Cell Non-Hodgkin Lymphoma (B-NHL). The purpose of this study is to evaluate the safety and clinical activity of UCART20x22 and determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D).
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
02/29/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: B-cell Non-Hodgkin Lymphoma (B-NHL)
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
Recruiting
This is an open-label, multi-center Phase 1b clinical study of oral AS-1763 in patients with CLL/SLL or B-cell NHL who have failed or are intolerant to ≥2 lines of systemic therapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/27/2024
Locations: University of Massachusetts Memorial Medical Center, Worcester, Massachusetts
Conditions: B-cell Malignancy, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma
61 - 72 of 114